Europska Unija - hrvatski - EMA (European Medicines Agency)

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - denga - cjepiva - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 i 4. korištenje dengvaxia moraju biti u skladu sa službenim preporukama.

Europska Unija - hrvatski - EMA (European Medicines Agency)

merial - živi atenuirani parvovirus duškog patka - imunomodulatori za aves, parvovirus patke, živa virusna cjepiva - patke - aktivna imunizacija patke kako bi se spriječila smrtnost1 i smanjiti gubitak težine i lezije parvovirozne patke i derzsyove bolesti. 1 u odsutnosti majčinskog protutijela.

Europska Unija - hrvatski - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - imunomodulatori za mačke, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Europska Unija - hrvatski - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - glecaprevir, pibrentasvir - hepatitis c, kronični - antivirusni lijekovi za sustavnu uporabu - maviret is indicated for the treatment of chronic hepatitis c virus (hcv) infection in adults and children aged 3 years and older. maviret coated granules is indicated for the treatment of chronic hepatitis c virus (hcv) infection in children 3 years and older.

Europska Unija - hrvatski - EMA (European Medicines Agency)

virbac s.a. - rekombinantni omega interferon mačjeg podrijetla - Иммуностимуляторы, - dogs; cats - dogsreduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age. catstreatment of cats infected with feline leukaemia virus (felv) and / or feline immunodeficiency virus (fiv), in non-terminal clinical stages, from the age of nine weeks. in a field study conducted, it was observed that there was:a reduction of clinical signs during the symptomatic phase (four months);a reduction of mortality:in anaemic cats, mortality rate of about 60% at four, six, nine and 12 months was reduced by approximately 30% following treatment with interferon;in non-anaemic cats, mortality rate of 50% in cats infected by felv was reduced by 20% following treatment with interferon. kod mačaka zaraženih virusom fiv, smrtnost je bila niska (5%) i nije bila pod utjecajem liječenja.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

sanofi pasteur, 14 espace henry vallee, lyon, francuska - virus žute groznice, soj 17d-204 (živi, atenuirani) - prašak i otapalo za otopinu za injekciju u napunjenoj štrcaljki - 1 doza = 0,5 ml - urbroj: 1 doza (0,5 ml) nakon rekonstitucije cjepiva sadrži virus žute groznice, soj 17d-204 (živi, atenuirani) ne manje od 1000 iu

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

sanofi pasteur, 14 espace henry vallee, lyon, francuska - soj virusa influence (inaktivirani, fragmentirani) tip a (h1n1) soj virusa influence (inaktivirani, fragmentirani) tip a (h3n2) soj virusa influence (inaktivirani, fragmentirani) tip b - suspenzija za injekciju u napunjenoj štrcaljki - 1 doza = 0,5 ml - urbroj: jedna doza (0,5 ml) sadrži 15 mikrograma hemaglutinina po soju virusa influence (inaktivirani, fragmentirani) za sezonu aktualnih sojeva, tip a (h1n1), tip a (h3n2) i dva soja tipa b

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

glaxosmithkline biologicals s.a., rue de l'institut 89, rixensart, belgija - soj virusa influence (inaktivirani, fragmentirani) tip a (h1n1) soj virusa influence (inaktivirani, fragmentirani) tip a (h3n2) soj virusa influence (inaktivirani, fragmentirani) tip b - suspenzija za injekciju u napunjenoj štrcaljki - 1 doza = 0,5 ml - urbroj: 1 doza (0,5 ml) sadrži 15 mikrograma hemaglutinina po soju virusa influence (inaktivirani, fragmentirani) za sezonu aktualnih sojeva tip a (h1n1), tip a (h3n2) i dva soja tipa b

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

viatris hrvatska d.o.o., koranska 2, zagreb, hrvatska - površinski antigeni inaktiviranog virusa influence soj a (h1n1) površinski antigeni inaktiviranog virusa influence soj a (h3n2) površinski antigeni inaktiviranog virusa influence soj b površinski antigeni inaktiviranog virusa influence soj b - suspenzija za injekciju u napunjenoj štrcaljki - 1 doza = 0,5 ml - urbroj: jedna doza (0,5 ml) sadrži 15 mikrograma hemaglutinina po soju virusa influence (površinski antigeni), za sezonu aktualnih sojeva tip a (h1n1), tip a (h3n2) i dva soja tipa b

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

bayer d.o.o. sarajevo - interferon beta-1b, rekombinantni - prašak i rastvarač za rastvor za injekciju - 0.25 mg/1 ml - 1 bočica sa praškom za rastvor za injekciju sadrži: 300 mikrograma (9 600 000 i.j.) što odgovara 250 mikrograma (8 000 000 i.j.)/ml nakon rekonstrukcije interferon beta1b, rekombinantni, liofilizovani